1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2003, Issue 2
  5. Article
Volume 2003, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Objective. To review the role of intravenous immunoglobulin (IVIG) in the prevention of recurrent miscarriage (RM). Methods. In a prospective controlled clinical tria], 40 women with a history of unexplained. RMwere treated with IVIG, according to a specific protocol and compared to another 40 women who had the same condition and treated with tender loving care and vitamins only. The birth of a child of more than 28 weeks gestation was considered a successful outcome.

Results. The overall success rate was 60% in the IVIG group compared with 52.6% in the control group (P = 0.65). The success rates for women with primary RM were 56.3% for IVIG group and 68.8% for the control group (P = 0.72). The success rates for women with secondary RM were 62.5% and 41.7% respectively (P = 0.25). None of the previous results is statistically significant.

Conclusion. Women with unexplained RM in general have a good prognosis. IVIG did not improve the prognosis significantly in the total group of patients compared with controls. However; further investigations are needed to explore whether the 21 % therapeutic benefit of IVIG in patients with secondary RM indicates that the treatment is efficient in this subset of patients.

© 2003 Saad, Shahata, Christiansen, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2003.2.9
2003-12-01
2021-04-14
Loading full text...

Full text loading...

References

  1. Carp HJA, Toder V, Gazit E, Ahiron A, Torchinski S, Mashiash S, Shoenfeld Y. Further experience with intravenous immunoglobulin in women with recurrent miscarriage and a poor prognosis. American Journal of Reproductive Immunology. 2001; 46::268–273.
     [Google Scholar]
  2. Christiansen OB, Mathiesen 0, Lauritsen JG, Grunnet N. Intravenous immunoglobulin treatment of women with multiple miscarriages. Human Reproduction. 1992; 7::718–722.
     [Google Scholar]
  3. Christiansen OB, Mathiesen 0, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG, Grunnet N. Placebocontrolled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Human Reproduction. 1995; 10::2690–2695.
     [Google Scholar]
  4. Christiansen OB, Klipatrick DC, Souter V, Warming K, Thiel S, Jensenius JC. Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scandinavian Journal of Immunology. 1998; 49::193–196.
     [Google Scholar]
  5. Christiansen OB, Pedersen B, Rosgaard A, Husth M. A randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin in the prevention of recurrent miscarriage: evidence for a therapeutic effect in women with secondary recurrent miscarriage. Human Reproduction. 2002; 17::809–816.
     [Google Scholar]
  6. Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of500 consecutive cases. Human Reproduction. 1994; 9::1328–1332.
     [Google Scholar]
  7. Coulam CB, Krysa L, Stem JJ, Bustillo M. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. American Journal of Reproductive Immunology. 1995; 34::333–337.
     [Google Scholar]
  8. Daya S, Gunby J, Clark DA. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: A metaanalysis. American Journal of Reproductive Immunology. 1998; 39:2:69–76.
     [Google Scholar]
  9. German RSA/IVIG group. Intravenous immunoglobulin in the prevention of recurrent miscarriage. British Journal of Obstetrics and Gynaecology. 1994; 101::1072–1077.
     [Google Scholar]
  10. Heine O, Mueller-Eckhardt G. Intravenous immunoglobulin in recurrent abortion. Clinical and Experimental Immunology. 1994; 97::39–42.
     [Google Scholar]
  11. Jablonowska B, Selbing A, Palfi M, Emerudh J, Kjellberg S, Lindton B. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: A double-blind placebocontrolled study. Human Reproduction. 1999; 14::838–841.
     [Google Scholar]
  12. Mueller-Eckhardt G, Heine O, Neppert J, Kunzel W, Mueller-Eckhardt C. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin. Vox Sang. 1989; 56::151–154.
     [Google Scholar]
  13. Mueller-Eckhardt G, Heine O, Polten BIVIG. to prevent recurrent spontaneous abortion. Lancet. 1991; 337::425–426.
     [Google Scholar]
  14. Perino A, Vassiliadis A, Vucetich A, Colacurci N, Menato G, Cignitti M, Semprini AE. Short-term therapy for recurrent abortion using intravenous immunoglobulins: Results of a double-blind placebo-controlled Italian study. Human Reproduction. 1997; 12::2388–2392.
     [Google Scholar]
  15. Pfeiffer KA, Fimmers R, Engels G, van der Yen H, Van der Yen K. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. Mol. Hum. Reprod. 2001; 7::373–378.
     [Google Scholar]
  16. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production on both leukemia inhibitory factor and type-2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med. 1998;:1020–1024.
     [Google Scholar]
  17. Ronda N, Hurez V, Kazatchkine MD. Intravenous immunoglobulin therapy for autoimmune and systemic inflammatory diseases. Vox Sang. 1993; 64::65–72.
     [Google Scholar]
  18. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunology Today. 1999; 20::114–118.
     [Google Scholar]
  19. Stephenson MD, Dreher K, Houlihan E, Wu V. Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: A prospective, randomized, double-blinded, placebo-controlled trial. American Journal of Reproductive Immunology. 1998; 39::82–88.
     [Google Scholar]
  20. Thornton CA, Ballow M. Safety of intravenous immunoglobulin. Achieve of Neurology. 1993; 50::135–136.
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2003.2.9
Loading
  • Article Type: Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error